A new approach to modeling complex biological systems
MIT engineers’ new model could help researchers glean insights from genomic data and other huge datasets.
MIT engineers’ new model could help researchers glean insights from genomic data and other huge datasets.
MIT researchers find that the first dose primes the immune system, helping it to generate a strong response to the second dose, a week later.
MIT scientists’ discovery yields a potent immune response, could be used to develop a potential tumor vaccine.
While women and men self-reported similar vaccination rates, unvaccinated women had less intention to get vaccinated than men.
Study shows metal-organic particles can both deliver vaccines and act as an adjuvant to generate a strong immune response at a lower dose.
MIT spinout Elicio developed a vaccine based on a lymph node-targeting approach first developed at the Koch Institute. Phase 1 solid tumor clinical trial results are promising so far.
Award honors “scientists who have made a transformational contribution toward the improvement of human health.”
Awarded $65.67 million from ARPA-H, the researchers will work to develop ingestible capsules that deliver mRNA and electric stimuli to treat metabolic disorders such as diabetes.
The inventor, entrepreneur, and philanthropist has co-founded and developed over 70 life-science and technology startups.
Using a DNA-based scaffold carrying viral proteins, researchers created a vaccine that provokes a strong antibody response against SARS-CoV-2.
Cancer nanomedicine was on display at the 2023 White House Demo Day.
Human volunteers will soon begin receiving an HIV vaccine that contains an adjuvant developed in Irvine’s lab, which helps to boost B cell responses to the vaccine.
The new approach could lead to intranasal vaccines for Covid-19 and other respiratory diseases.
The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.
A pilot-scale system, enabled by an $82 million award from the FDA, aims to accelerate the development and production of mRNA technologies.